GlassScriptPhysician profile
Daniel Joseph Lor
NPI 1417627415
$2,302.07
in general payments reported to CMS, 2019-2025
19 companies · $999 in 2025
The $999 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $418 · 2024: $885 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $460.13 | 2023-2025 | Dupixent, Libtayo |
| Incyte Corporation | $321.87 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $255.28 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $221.52 | 2023-2024 | Sotyktu |
| Organon LLC | $208.56 | 2024-2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $194.24 | 2023-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $181.65 | 2024-2025 | |
| Organogenesis INC. | $106.21 | 2024 | Cygnus Dual |
| Genzyme Corporation | $74.53 | 2024-2025 | |
| Boston Scientific Corporation | $46.68 | 2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $37.55 | 2024-2025 | |
| Almirall LLC | $35.42 | 2024-2025 | Seysara |
| Leo Pharma INC. | $31.12 | 2025 | Anzupgo |
| Mayne Pharma Commercial LLC | $27.94 | 2024 | |
| Ucb, INC. | $22.33 | 2025 | Bimzelx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.92 | 2023 | Spevigo |
| Becton, Dickinson and Company | $20.20 | 2024 | Venclose Maven Catheter |
| Biofrontera INC. | $19.27 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $16.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.